Searchable abstracts of presentations at key conferences in endocrinology

ea0055p11 | Poster Presentations | SFEEU2018

A challenging case of rapidly enlarging thyroid mass

Rehman Tejhmal , Hameed Ali , Kim Dae , Pettengell Ruth , Bano Gul

A 60 year old Caucasian woman presented with a three month history of rapidly enlarging neck swelling and hoarseness of voice. Her past medical history included Hypothyroidism. Her neck ultrasound scans showed 3.5 cm left thyroid nodule with bilateral lymphadenopathy (U5). The Fine needle aspiration (FNA) revealed densely grouped variable sized irregular epithelial cells with nuclear atypia and spindle shaped fragments with focal areas of lymphocytic thyroiditis. The different...

ea0090ep129 | Calcium and Bone | ECE2023

Prediabetes is associated with lower trabecular bone score (TBS): Comparison of TBS according to the prediabetes phenotype

Choi Yong Jun , Ha Kyounghwa , Kim Dae Jung , Chung Yoon-Sok

Objective: Diabetes mellitus (DM) is known to be associated with a lower trabecular bone score (TBS) and an increased risk of fracture. However, little is known regarding whether it is associated with poor bone results in pre-diabetic individuals. Despite the fact that both IFG and IGT are characterized by insulin resistance and β-cell dysfunction, the metabolic abnormalities are quite distinct between the two disorders. Impaired fasting glucose (IFG) was marked by dysfun...

ea0094p381 | RET | SFEBES2023

RET inhibitors in thyroid cancer: A single-institution experience

Cheng Leslie , Hoy Sonja , Hyer Stephen , Morganstein Daniel , Kim Dae , Howe Wong Kee , Newbold Kate

Background: Mutations in the RET proto-oncogene occur in about 70% of medullary thyroid cancers (MTC) and is central in its pathogenesis. Two highly selective RET inhibitors, selpercatinib and pralsetinib, are FDA/EMA-approved in RET-altered thyroid cancers. We share our experience of these drugs in metastatic MTC.Methods: Data were collected retrospectively from 19 patients commenced on selective RET inhibitors for MTC ...

ea0015p176 | Endocrine tumours and neoplasia | SFEBES2008

A novel mechanism of thyroid tumorigenesis based on inactivation of p53 by the PTTG-binding factor PBF

Read Martin , Turnell Andy , Kim Dae , Watkins Rachel , Smith Vicki , Fong Jim , Watkinson John , Boelaert Kristien , Franklyn Jayne , McCabe Chris

The pituitary tumor transforming gene binding factor (PBF) is a poorly characterised gene that is over-expressed in pituitary and thyroid tumours. Recently, we showed that subcutaneous expression of PBF elicits tumours in nude mice, and expression correlates with thyroid tumour recurrence in man. Given the established role of ionising radiation in thyroid tumourigenesis, we have now investigated the relationship between PBF and the tumour suppressor gene p53, a central compone...

ea0081p66 | Diabetes, Obesity, Metabolism and Nutrition | ECE2022

The role of empagliflozin in palmitate-induced ER stress and apoptosis in H9C2 cells

Jeong Jae Yeop , Choi Sung-E , Song Min Woo , Ho Park Suck , Kang Yup , Ho Kim Tae , Ahn So-Yeon , Jin Kim Hae , jin Han Seung , Jeon Ja Young , Lee Nami , Jung Kim Dae , Lee Kwan-Woo

Aim/hypotheses: Ectopic lipid accumulation in the heart contributes to the abnormal function of the heart and to the death of cardiomyocytes. Saturated FFA is one of the most important causes of death in cardiomyocytes. Although empagliflozin has been reported to be beneficial for people with diabetic complications and/or CVD, it has not been confirmed as to how it affects cardiomyocytes death by FFA. This study was designed to evaluate the protective effects of SGLT2 inhibito...